Arrowhead Pharmaceuticals マネジメント
マネジメント 基準チェック /34
Arrowhead Pharmaceuticalsの CEO はChris Anzaloneで、 Dec2007年に任命され、 の在任期間は 16.92年です。 の年間総報酬は$ 9.92Mで、 9.1%給与と90.9%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の2.99%を直接所有しており、その価値は$ 67.91M 。経営陣と取締役会の平均在任期間はそれぞれ6.4年と14年です。
主要情報
Chris Anzalone
最高経営責任者
US$9.9m
報酬総額
| CEO給与比率 | 9.1% |
| CEO在任期間 | 16.9yrs |
| CEOの所有権 | 3.0% |
| 経営陣の平均在職期間 | 6.4yrs |
| 取締役会の平均在任期間 | 14yrs |
経営陣の近況
Recent updates
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?
Oct 04
Arrowhead Pharmaceutical: Driving To Commercialization
Jul 26Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jun 12Arrowhead Pharmaceuticals: Hoping Something Sticks
May 27Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?
May 21Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point
May 17Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding
Apr 03Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
Mar 30Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package
Mar 08Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Feb 19Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy
Jan 21Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now
Dec 25Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?
Sep 19Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up
Apr 17Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now
Mar 10A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Jan 24We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn
Oct 24Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities
Sep 12Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming
Aug 23Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease
Aug 17Arrowhead Pharmaceuticals: An RNAi Name To Know
Jul 28Arrowhead Pharmaceuticals names internal officer as new COO
Jul 20Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs
Jul 05CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$539m |
| Mar 31 2024 | n/a | n/a | -US$471m |
| Dec 31 2023 | n/a | n/a | -US$297m |
| Sep 30 2023 | US$10m | US$903k | -US$205m |
| Jun 30 2023 | n/a | n/a | -US$181m |
| Mar 31 2023 | n/a | n/a | -US$150m |
| Dec 31 2022 | n/a | n/a | -US$155m |
| Sep 30 2022 | US$12m | US$863k | -US$176m |
| Jun 30 2022 | n/a | n/a | -US$154m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | n/a | n/a | -US$183m |
| Sep 30 2021 | US$25m | US$837k | -US$141m |
| Jun 30 2021 | n/a | n/a | -US$126m |
| Mar 31 2021 | n/a | n/a | -US$110m |
| Dec 31 2020 | n/a | n/a | -US$103m |
| Sep 30 2020 | US$14m | US$786k | -US$85m |
| Jun 30 2020 | n/a | n/a | -US$24m |
| Mar 31 2020 | n/a | n/a | US$10m |
| Dec 31 2019 | n/a | n/a | US$53m |
| Sep 30 2019 | US$2m | US$674k | US$68m |
| Jun 30 2019 | n/a | n/a | US$46m |
| Mar 31 2019 | n/a | n/a | US$10m |
| Dec 31 2018 | n/a | n/a | -US$29m |
| Sep 30 2018 | US$2m | US$643k | -US$54m |
報酬と市場: Chrisの 総報酬 ($USD 9.92M ) は、 US市場 ($USD 5.43M ) の同規模の企業の平均を上回っています。
報酬と収益: Chrisの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Chris Anzalone (55 yo)
16.9yrs
在職期間
US$9,918,093
報酬
Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 16.9yrs | US$9.92m | 2.99% $ 67.9m | |
| Chief Financial Officer | 14.8yrs | US$3.12m | 0.19% $ 4.3m | |
| COO, General Counsel & Secretary | 9.9yrs | US$3.31m | 0.23% $ 5.2m | |
| Chief of Discovery & Translational Medicine | no data | US$3.05m | 0.16% $ 3.7m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | データなし | データなし | |
| Head of Investor Relations & VP | no data | データなし | データなし | |
| Director of Communications | 19.3yrs | データなし | データなし | |
| Chief Medical Scientist | less than a year | US$16.34m | データなし | |
| Head of Toxicology & VP | no data | データなし | データなし | |
| Head of Tax | 2.8yrs | データなし | データなし | |
| SVP of Cardiovascular & Head of Metabolic Franchise | no data | データなし | データなし | |
| VP & Treasurer | 2.8yrs | データなし | データなし |
6.4yrs
平均在職期間
59yo
平均年齢
経験豊富な経営陣: ARWRの経営陣は経験豊富で経験豊富です（平均在職期間は6.4年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO, President & Director | 16.9yrs | US$9.92m | 2.99% $ 67.9m | |
| Founder and Founder & Director of Insert Therapeutics Inc & Calando | no data | データなし | データなし | |
| Chairman of the Board | 14yrs | US$474.60k | 0.11% $ 2.6m | |
| Independent Lead Director | 12.9yrs | US$459.60k | 0.074% $ 1.7m | |
| Independent Director | 6.8yrs | US$469.60k | 0.026% $ 601.1k | |
| Member of Hepatitis B Clinical Advisory Board | no data | データなし | データなし | |
| Chairman of Hepatitis B Clinical Advisory Board | no data | データなし | データなし | |
| Independent Director | 14.3yrs | US$459.60k | 0.037% $ 837.0k | |
| Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board | no data | データなし | データなし | |
| Member of Hepatitis B Clinical Advisory Board | no data | データなし | データなし | |
| Member of Hepatitis B Clinical Advisory Board | no data | データなし | データなし | |
| Member of Hepatitis B Clinical Advisory Board | no data | データなし | データなし |
14.0yrs
平均在職期間
65yo
平均年齢
経験豊富なボード: ARWRの 取締役会 は経験豊富で 経験豊富 です ( 14年の平均在任期間)。